{"id":46137,"date":"2026-07-28T05:00:00","date_gmt":"2026-07-28T03:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=dde05dc0d9273ff2a86f7249c0e0bb10"},"modified":"2026-07-28T05:00:00","modified_gmt":"2026-07-28T03:00:00","slug":"investor-alert-securities-class-action-filed-against-procept-biorobotics-corporation-investors-encouraged-to-contact-kirby-mcinerney-llp","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=46137","title":{"rendered":"INVESTOR ALERT: Securities Class Action Filed Against PROCEPT BioRobotics Corporation \u2013 Investors Encouraged to Contact Kirby McInerney LLP"},"content":{"rendered":"

NEW YORK--(BUSINESS WIRE)--$PRCT<\/a> #classactionlawsuit<\/a>--The law firm of Kirby McInerney LLP<\/a> announces that a class action lawsuit has been filed on behalf of investors who acquired PROCEPT BioRobotics Corporation (\u201cProcept\u201d or the \u201cCompany\u201d) (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (\u201cthe Class Period\u201d).<\/p><\/a><\/a>

\nIf you suffered a loss on your Procept investments, you have until September 22, 2026<\/b> to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. If you choose to take no action, you may remain an absent class member. For more information about the lawsuit:<\/p>

\n[CONTACT THE FIRM IF YOU SUFFERED A LOSS<\/a>]<\/p>

\nWhat Is This Lawsuit About? <\/b>The lawsuit alleges that Procept made materially false and misleading statements and\/or failed to disclose: (i) that during the Class Period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept\u2019s undisclosed discount program had artificially and unsustainably inflated the Company\u2019s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept\u2019s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept\u2019s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept\u2019s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of the foregoing, Defendants\u2019 representations during the Class Period regarding Procept\u2019s handpiece unit sales and the utilization of Procept\u2019s field Systems were materially overstated; (vi) that, as a result of the foregoing, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of the foregoing, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.<\/p>

\nOn August 6, 2025, Procept announced earnings results for its second fiscal quarter of 2025, revealing that handpiece unit shipments had unexpectedly deteriorated as the Company has sold approximately 12,750 handpieces in the U.S. during the quarter. That same day, Procept announced it expected to ship 13,350 units the following quarter, down from consensus estimates of over 13,840 units. Additionally, CEO Reza Zadno announced that Procept was eliminating the role of Chief Commercial Officer. On this news, Procept\u2019s stock price fell from $45.69 per share on August 6, 2025 to close at $38.41 per share on August 8, 2025, a decline of approximately 16%.<\/p>

\nOn November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that the Company had sold 13,225 handpieces, missing the Company\u2019s guidance set during the previous quarter. The Company also announced it was reducing its annual handpiece sales guidance by 1,000 units, from 53,000 to 52,000 units. Additionally, when pressed by analysts<\/p>

\nregarding the lowered handpiece guidance, CEO Larry L. Wood admitted that Procept had not \u201cbeen managing customer inventory by establishing par levels\u201d and that some customers were \u201cprobably carrying too much.\u201d On this news, Procept\u2019s stock price fell from $35.02 per share on November 4, 2025 to close at $31.30 per share on November 6, 2026, a decline of over 10%.<\/p>

\nOn February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year, revealing that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential that had grown over time, resulting in cumulative excess field inventory of over 10,000 units. As a result, Procept handpiece unit sales in the U.S. declined from 13,225 units in the third quarter to 9,400 units in the fourth quarter, a nearly 30% decline. Additionally, Procept revealed that the Company was eliminating a longstanding (but previously undisclosed) discount program that had incentivized customers to place bulk orders \u201c[during] the final weeks\u201d of every quarter, impairing the Company\u2019s ability to make additional handpiece sales in subsequent quarters. On this news, Procept\u2019s stock price fell over two trading days, from $27.84 per share on February 25, 2026 to close at $22.69 per share on February 27, 2026, a decline of over 18%.<\/p>

\n[LEARN MORE ABOUT THE LAWSUIT<\/a>]<\/p>

\nThe Lead Plaintiff Appointment Process. <\/b>The federal securities laws permit any investor who acquired eligible securities during the class period to seek appointment as lead plaintiff in a <\/i>class action lawsuit. Learn more about the lead plaintiff process and eligibility requirements here<\/a>. Courts typically appoint the investor(s) with the largest financial loss in the case and the ability to represent the class rather than investors with simply the largest investment portfolio. Courts regularly appoint individual investors, whether acting alone or as a group, as lead plaintiffs. The rights of any investor who bought shares during the class period are generally already protected. However, lead plaintiffs have the power to influence case strategy and have a say in settlement decisions, as well as decisions concerning allocation of settlement funds among class members.<\/p>

\n[LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS<\/a>]<\/p>

\nWhat Should I Do? <\/b>If you purchased or otherwise acquired Procept securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro<\/a> of Kirby McInerney LLP<\/a> by email at investigations@kmllp.com<\/a>, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.<\/p>

\nKirby McInerney LLP<\/a> is a New York-based plaintiffs\u2019 law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm\u2019s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP\u2019s website<\/a>.<\/p>

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

\nKirby McInerney LLP\nLauren Molinaro, Esq.\n212-699-1171\nhttps:\/\/www.kmllp.com<\/a>https:\/\/securitiesleadplaintiff.com\/<\/a>investigations@kmllp.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–$PRCT #classactionlawsuit–The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired PROCEPT BioRobotics Corporation (\u201cProcept\u201d or the \u201cCompany\u201d) (NASDAQ: PRC…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-46137","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/46137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46137"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/46137\/revisions"}],"predecessor-version":[{"id":46138,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/46137\/revisions\/46138"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}